-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Beyond Somatic Mutations in the Pathogenesis of Myeloid Neoplasia

Program: Scientific Program
Session: Co-Operativity in the Pathogenesis of Myeloid Malignancies
Saturday, December 9, 2023, 2:00 PM-3:15 PM

Mark A. Dawson, MBBS, PhD, FRACP, FRCPA

Cancer Research Division, Peter Maccallum Cancer Centre, Melbourne, VIC, Australia

Disclosures: Dawson: Cambridge Epigenetix / Biomodal: Consultancy, Membership on an entity's Board of Directors or advisory committees; Storm Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Consultancy, Membership on an entity's Board of Directors or advisory committees.

See more of: Co-Operativity in the Pathogenesis of Myeloid Malignancies
See more of: Scientific Program
<< Previous Presentation | Next Presentation